Coya Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $98.52M
- P/E (TTM)
- –
- Dividend yield
- –
About Coya Therapeutics
Pharmaceutical Preparations, SIC 2834
Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies designed to enhance the function of regulatory T cells, or Tregs. The company explores three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Its pipeline addresses neurodegenerative, autoimmune, and metabolic diseases, with primary focus on conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Its lead candidate, COYA 302, is a combination biologic utilizing low-dose interleukin-2 alongside a fusion protein. Another candidate, COYA 303, combines low-dose interleukin-2 with a GLP-1 receptor agonist for inflammatory conditions. Because its product candidates remain in clinical and preclinical development, the company does not have commercial customers.
The company operates through strategic research collaborations, licensing agreements, and partnerships, including research work conducted with Houston Methodist Hospital. Its clinical investigations, such as the multicenter ALSTARS Phase 2 trial, take place in the United States. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Coya Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Coya Therapeutics, Inc.
- Headquarters
- Houston, TX
- Address
- 12645 Memorial Dr., Suite F1 #305 77024
- Phone
- (650) 739-3939
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weaver and Tidwell, L.L.P., New York, NY
Stock & identifiers
- Ticker
- COYA
- Exchange
- Nasdaq
- IPO date
- Dec 30, 2022
- Shares outstanding
- 23M, Aug 7, 2026
- Public float
- $89.42M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1835022
- CUSIP
- 22407B108
- ISIN
- US22407B1089
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Howard Berman | Executive Chairman, Director | 949,338 |
| Arun Swaminathan | Chief Executive Officer, Director | 10,000 |
| David S. Snyder | Chief Financial Officer | 8,800 |
| Fred Grossman | Chief Medical Officer | 2,710 |
| Mark H. Pavao | Director | – |
| Ann Lee | Director | 33,958 |
| Wilbur L. Ross Jr | Director | 165,016 |
| Dieter Weinand | Director | – |
| Dov A. Goldstein Md | Director | 27,557 |
| Anabella Villalobos | Director | 10,000 |
Employees
Headcount reported in annual reports
“We have eight full-time employees, and utilize consultants, contract research organizations and third parties to perform our pre-clinical studies, clinical studies, administrative, and financial functions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 30, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 27, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |